Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
SEATTLE, May 01, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its financial results for the first quarter of 2017 before the opening of the U.S. financial markets on Tuesday, May 9, 2017. Following the financial results announcement, members of management will host a conference call and live audio webcast to discuss the results and provide a general corporate update. Access to the conference call can be obtained as follows:
Live access on Tuesday, May 9, 2017
5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time
Telephone: +1 (877) 280-7291 (domestic) or +1 (707) 287-9361 (international)
Live webcast and replay will be available via the “Events & Presentations” page of the “News & Events” section of the Cascadian Therapeutics’ website at www.cascadianrx.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.
Cascadian Therapeutics Inc. Investor and Media Contact: Monique Greer Cascadian Therapeutics 206-801-2107 [email protected]
